{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:08Z","timestamp":1786987748826,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.drugalcdep.2019.107697","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T07:23:11Z","timestamp":1572679391000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5705-2026","authenticated-orcid":false,"given":"Amy","family":"Peacock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8470","authenticated-orcid":false,"given":"Natasa","family":"Gisev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Memedovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-7673","authenticated-orcid":false,"given":"Briony","family":"Larance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.107697_bib0005","series-title":"3101.0 - Australian Demographic Statistics","author":"Australian Bureau of Statistics","year":"2017"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pme.12524","article-title":"Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment","volume":"16","author":"Butler","year":"2015","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/AJP.0000000000000067","article-title":"Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse","volume":"30","author":"Cepeda","year":"2014","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0020","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jpain.2013.05.010","article-title":"Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study","volume":"14","author":"Cepeda","year":"2013","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.drugalcdep.2005.10.020","article-title":"Abuse of prescription drugs and the risk of addiction","volume":"83","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5055\/jom.2012.0139","article-title":"Assessment of the abuse of tapentadol immediate release: the first 24 months","volume":"8","author":"Dart","year":"2012","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0035","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/pm\/pnv032","article-title":"Diversion and illicit sale of extended release tapentadol in the United States","volume":"17","author":"Dart","year":"2015","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2012.04317.x","article-title":"Differences between opioids: pharmacological, experimental, clinical and economical perspectives","volume":"75","author":"Drewes","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0050","series-title":"Australian Pharmaceutical Index: IMS Plus Workshop Manual","author":"IMS Health","year":"2009"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.12937","article-title":"Twenty\u2010five years of prescription opioid use in Australia: a whole\u2010of\u2010population analysis using pharmaceutical claims","volume":"82","author":"Karanges","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","article-title":"Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally\u2010acting analgesics on the horizon?","volume":"14","author":"Kress","year":"2010","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1465-3362.2010.00283.x","article-title":"Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non\u2010adherence and aberrant medication\u2010related behaviours","volume":"30","author":"Larance","year":"2011","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S2215-0366(18)30003-8","article-title":"The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study","volume":"5","author":"Larance","year":"2018","journal-title":"Lancet Psychiat."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0075","first-page":"S67","article-title":"American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/pme.12547","article-title":"Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse","volume":"16","author":"McNaughton","year":"2015","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jat\/bky027","article-title":"The increasing use and abuse of tapentadol and its incorporation into a validated quantitative method","volume":"42","author":"Partridge","year":"2018","journal-title":"J.Anal. Tox"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0095","series-title":"Australian Drug Trends 2018: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews","author":"Peacock","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0100","first-page":"1011","article-title":"Tapentadol and dual pain inhibition: a new strategy for pain relief in Australia","volume":"2","author":"Perglozzi","year":"2015","journal-title":"Chronic Dis. Int."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0105","series-title":"Tapentadol, Tablet, 50mg, 100mg, 150mg, 200mg and 250mg (as Hydrochloride) (sustained Release), Palexia SR\u00ae - November 2013","author":"Pharmaceutical Benefits Scheme","year":"2013"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0110","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1185\/03007995.2011.611494","article-title":"Systematic review of tapentadol in chronic severe pain","volume":"27","author":"Riemsma","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0115","series-title":"Australian Public Assessment Report for Tapentadol","author":"Therapeutic Goods Administration","year":"2011"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0120","series-title":"FDA Opioids Action Plan","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/JPR.S14842","article-title":"Tapentadol extended-release for treatment of chronic pain: a review","volume":"4","author":"Vadivelu","year":"2011","journal-title":"J. Pain Res."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5055\/jom.2010.0015","article-title":"Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain","volume":"6","author":"Vorsanger","year":"2009","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jpain.2017.11.007","article-title":"Assessment of tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance (RADARS) system","volume":"19","author":"Vosburg","year":"2017","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2019.107697_bib0140","series-title":"Tapentadol: Critical Review Report","author":"World Health Organisation","year":"2014"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619304740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619304740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:02:25Z","timestamp":1759827745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871619304740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":28,"alternative-id":["S0376871619304740"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107697","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}